Lessons from Covid-19 Drug Development

The video discusses Regeneron's role in the pandemic, focusing on the rapid development of monoclonal antibodies. It highlights the challenges faced in drug development, particularly with the emergence of variants like Omicron. The discussion covers the uptake of treatments, regulatory and manufacturing hurdles, and issues related to drug pricing. The video concludes with insights on future preparedness for pandemics.

What lessons were learned from the early use of monoclonal antibodies during the pandemic?

What are the proposed next steps for Regeneron in response to new variants?

How does Regeneron plan to address drug pricing concerns in the future?

What is the importance of having a robust manufacturing capacity for future pandemics?